The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01926041|
Recruitment Status : Recruiting
First Posted : August 20, 2013
Last Update Posted : January 28, 2016
Diabetes mellitus (DM) has been established to contribute to cardiovascular comorbidities, malignancies and higher mortalities. The management of DM is not limited to aggressively controlling sugar levels after the diagnosis; instead, should be emphasized more on effective modification for prediabetics. Smoking cessation were also demonstrated to improve insulin resistance. Nowadays, the 2nd-generation cessation program in Taiwan brings higher accessibility. However, there is little evidence on the long-term health outcomes of combining smoking cessation and coach-assisted lifestyle change for the prediabetics in the community.
The present new project extends the original pilot project (NSC 102-2628-B-002-046-MY2 and MOST 104-2314-B-002 -072) from August of 2013. The investigators have been making efforts to promote this project by cooperating with primary care doctors of the community medical groups and corporate nurses. Over 446 prediabetic smokers will be enrolled by July of 2017. The invention includes smoking cessation clinics for up to 16 weeks (from January to December of 2017) and coach-assisted lifestyle change (from January of 2017 to July of 2020 and later) for every participant joining intervention. The lifestyle coaches will help the participants in intervention group reach the goal of at least a 7 percent weight loss within the first 6 months. All smokers with prediabetes in intervention and self-management group are provided with educational materials for lifestyle change. All prediabetic smokers are prospectively followed up every 6 months till July of 2020 and later for smoking status, anthropometric indices and blood tests.
Regarding the potential contribution to the national socio-economic development, this project will strengthen the motivation of smoking cessation in prediabetic smokers. Academically, cox regression will be used to investigate the effectiveness of the smoking cessation combined with coach-assisted lifestyle change on DM prevention in smokers with prediabetes. This prospective project will contribute to community-based diabetes research in preventive medicine.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Cigarette Smoking Prediabetes||Other: Smoking cessation clinics Behavioral: Coach-assisted lifestyle change||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||446 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2020|
The invention includes smoking cessation clinics for up to 16 weeks (from January to December of 2017) and coach-assisted lifestyle change (from January of 2017 to July of 2020 and later) for every participant joining intervention. Each participant in intervention group receives counseling for individualized smoking cessation techniques at each visit. In addition, each participant is assigned two lifestyle coaches giving weekly and standardized instruction in diet and physical activity to help reach the goals of at least a 7 percent weight loss within the first 6 months. Each coach of physical activity offers supervised physical activity sessions at least two times per week (perhaps through cell phone apps). We do not prescribe the nicotine replacement therapy because it may induce insulin resistance and confound our study outcome. Bupropion is not available for smoking cessation in our institutions.
|Other: Smoking cessation clinics Behavioral: Coach-assisted lifestyle change|
No Intervention: Self-management
Participants who decide NOT to attend the intervention program are classified as self-management group. All smokers with prediabetes in intervention and self-management group are provided with educational materials for lifestyle change. They are still provided with educational materials of standardized diet and exercise. They are prospectively followed up every 6 months till July of 2020 and later for FTND scores, breath CO levels, anthropometric indices and blood tests (Table 1, Figure 1). The skills of body weight self-management (with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week)19 are delivered through educational materials.
- Diagnosis of diabetes mellitus by ADA criteria [ Time Frame: at least 3 years (from Aug 1, 2013) ]The primary outcome is DM, defined as having repeatedly at least one of the following criteria: 1) plasma glucose ≥126 mg/dL (7.0 mmol/L) in the fasting state; 2) plasma glucose ≥200 mg/dL (11.1 mmol/L) randomly with hyperglycemic symptoms or two hours after a 75-g oral glucose load; 3) A1C ≥6.5%;20 or under medications for physician-diagnosed DM.
- A1C Change and Regression to Normoglycemia [ Time Frame: at least 3 years (from Aug 1, 2013) ]Normoglycemia is defined as having all the following for over 3 months: 1) plasma glucose <100 mg/dL (5.6 mmol/L) in the fasting state; 2) plasma glucose <140 mg/dL (7.8 mmol/L) two hours after a 75-g oral glucose load; 3) A1C <5.7%, in the absence of diabetic medications.
- Diagnoses of cardiovascular events [ Time Frame: at least 3 years (from Aug 1, 2013) ]by specialists
- Chronic kidney disease progression [ Time Frame: at least 3 years (from Aug 1, 2013) ]including change in eGFR and microalbuminuria
- Chronic hepatitis or cirrhosis progression [ Time Frame: at least 3 years (from Aug 1, 2013) ]confirmed by ultrasonography or advanced image or pathology studies
- Malignancy incidence [ Time Frame: at least 3 years (from Aug 1, 2013) ]confirmed by national cancer registry system
- All-cause mortality [ Time Frame: at least 3 years (from Aug 1, 2013) ]Deaths are ascertained by computer linkage to the national death registry (death certificates were created by the Department of Health, Taiwan) using ID numbers and these death certificates have been validated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01926041
|Contact: Chien-Hsieh Chiang, MD, MPHfirstname.lastname@example.org|
|National Taiwan University Hospital Yun-Lin branch||Recruiting|
|Yunlin, Taiwan, 640|
|Contact: Chien-Hsieh Chiang, MD, MPH +886-9-20511256 email@example.com|
|Contact: Kuo-Chin Huang, MD, PhD|
|Principal Investigator: Chien-Hsieh Chiang, MD, MPH|
|Sub-Investigator: Kuo-Chin Huang, MD, PhD|
|Principal Investigator:||Chien-Hsieh Chiang, MD, MPH||National Taiwan Univeristy Hospital Yun-Lin Branch & College of Medicine|